Holocene Advisors LP Sells 530,106 Shares of Eli Lilly and Company $LLY

Holocene Advisors LP lowered its position in Eli Lilly and Company (NYSE:LLY) by 78.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 149,593 shares of the company’s stock after selling 530,106 shares during the period. Holocene Advisors LP’s holdings in Eli Lilly and Company were worth $114,139,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LLY. Hughes Financial Services LLC increased its holdings in shares of Eli Lilly and Company by 20.3% in the third quarter. Hughes Financial Services LLC now owns 379 shares of the company’s stock valued at $289,000 after purchasing an additional 64 shares in the last quarter. Humankind Investments LLC lifted its holdings in Eli Lilly and Company by 13.1% during the 3rd quarter. Humankind Investments LLC now owns 4,959 shares of the company’s stock worth $3,784,000 after buying an additional 574 shares in the last quarter. Gotham Asset Management LLC lifted its holdings in Eli Lilly and Company by 11.6% during the 3rd quarter. Gotham Asset Management LLC now owns 8,016 shares of the company’s stock worth $6,116,000 after buying an additional 830 shares in the last quarter. Fairfield Bush & CO. boosted its position in Eli Lilly and Company by 4.6% in the 3rd quarter. Fairfield Bush & CO. now owns 2,956 shares of the company’s stock valued at $2,255,000 after buying an additional 131 shares during the last quarter. Finally, Fayez Sarofim & Co boosted its position in Eli Lilly and Company by 2.5% in the 3rd quarter. Fayez Sarofim & Co now owns 436,162 shares of the company’s stock valued at $332,792,000 after buying an additional 10,522 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on LLY shares. Scotiabank reiterated an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Guggenheim upped their target price on shares of Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Barclays began coverage on shares of Eli Lilly and Company in a research note on Thursday, February 19th. They issued an “overweight” rating and a $1,350.00 target price on the stock. Argus lifted their price target on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, CICC Research boosted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 11th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,229.59.

Eli Lilly and Company Price Performance

Shares of LLY opened at $985.10 on Monday. The stock has a market cap of $930.74 billion, a P/E ratio of 42.92, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The stock’s 50-day moving average price is $1,037.28 and its two-hundred day moving average price is $952.32. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same period in the prior year, the business posted $5.32 EPS. Eli Lilly and Company’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Big, long‑term capacity bet in China: Lilly’s planned $3 billion, decade‑long buildout in China is being viewed as a strategic way to secure supply, win share in the fast‑growing GLP‑1 market there, and defend margins versus local competitors — a clear revenue runway catalyst. The Real Reason Eli Lilly Is Pouring $3 Billion Into China
• Positive Sentiment: Policy and access tailwinds: CMS expansion of Medicare access to Zepbound and Mounjaro broadens the addressable patient base and reduces a key barrier to volume growth for Lilly’s injectable GLP‑1s. This supports upside to near‑term sales forecasts. Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro
• Positive Sentiment: Commercial & product expansion moves: Employer Connect and LillyDirect aim to unlock employer coverage and lower out‑of‑pocket friction for Zepbound, which could materially increase uptake if employers adopt the program. Combined with positive head‑to‑head oral GLP‑1 data for orforglipron, this strengthens the multi‑product growth story. Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand
• Positive Sentiment: Clinical pipeline progress: Lilly advanced a Phase‑1 study of eloralintide in high‑risk kidney patients — additional indications or safety/efficacy data can expand uses and support valuation beyond obesity/diabetes franchises. Lilly Advances Eloralintide Study in High-Risk Kidney Patients: What Investors Should Know
• Positive Sentiment: Manufacturing footprint expansion: Smaller regional investments (e.g., Korea, Japan plant expansion) further de‑risk supply and support global launch scale for next‑gen GLP‑1s. These moves reduce disruption risk and help defend market share. Eli Lilly invests $500 million in Korea’s biotech growth
• Neutral Sentiment: Valuation / stock structure chatter: Continued outperformance has people speculating about a stock split (accessibility for retail investors), which is psychology‑driven and may influence retail flows but doesn’t change fundamentals. 3 Stocks That Could Be Next to Announce a Stock Split
• Negative Sentiment: Safety/supply headline risk: Lilly warned about an unknown impurity found in compounded tirzepatide mixed with vitamin B12 — this raises short‑term PR/regulatory risk and could spur use‑restrictions or additional scrutiny of compounding practices. Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
• Negative Sentiment: Momentum concerns: Some analysts/commentary note weakening trading momentum since November — a reminder that lofty multiples and rate/flow dynamics can pressure the stock if sentiment turns. Eli Lilly Reaching For Peak GLP-1 Euphoria: Rotten Trading Momentum Since November

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.